替格瑞洛对非ST段抬高型急性冠脉综合征患者纤维蛋白原、高敏C反应蛋白的影响

高磊; 李卫华; 谢强; 黄峥嵘

doi:10.13201/j.issn.1001-1439.2017.02.011

替格瑞洛对非ST段抬高型急性冠脉综合征患者纤维蛋白原、高敏C反应蛋白的影响

- 厦门大学附属第一医院心内科(福建厦门, 361003)

详细信息

通讯作者: 高磊,E-mail:gaoleidoctor@126.com

中图分类号: R542.2

收稿日期: 2016-08-15

修回日期: 2016-11-21

The effect of ticagrelo on fibrinogen and hs-CRP in patients with non-ST-elevation acute coronary syndromes

- Department of Cardiology, the First Affiliated Hospital of Xiamen University, Xiamen, 361003, China

More Information

Corresponding author: GAO Lei, E-mail: gaoleidoctor@126.com

Received Date: 15 August 2016

Revised Date: 21 November 2016

摘要

摘要: 目的:探讨替格瑞洛对非ST段抬高型急性冠脉综合征(NSTE-ACS)患者纤维蛋白原(Fib)和高敏C反应蛋白(hs-CRP)的影响。方法:入选NSTE-ACS患者128例,随机分为替格瑞洛组(66例)和氯吡格雷组(62例),观察2组治疗前、治疗后第3天、第7天Fib和hs-CRP的变化。结果:治疗3 d后,替格瑞洛组与氯吡格雷组比较Fib[(4.02±0.13) g/L vs(4.10±0.15) g/L]和hs-CRP[(18.7±5.5) mg/L vs (19.6±5.7) mg/L]有下降趋势,差异无统计学意义(P>0.05),治疗7 d后,替格瑞洛组Fib[(3.06±0.16) g/L vs (3.52±0.19) g/L]和hs-CRP[(7.1±4.2) mg/L vs (9.58±4.6) mg/L]下降更明显,差异有统计学意义(P＜0.05)。结论:对于NSTE-ACS患者,替格瑞洛较氯吡格雷有更强的血栓抑制作用和抗炎作用。
- 非ST段抬高型急性冠脉综合征 /
- 替格瑞洛 /
- 氯吡格雷 /
- 纤维蛋白原 /
- 高敏C反应蛋白
Abstract: Objective:To investigate the effects of ticagrelo on fibrinogen(Fib) and high-sensitive C-reactive protein(hs-CRP) in patients with non-ST-elevation acute coronary syndromes(NSTE-ACS). Method:One hundred and twenty-eight cases of NSTE-ACS were randomly divided into ticagrelo group (n=66) and clopidogrel group (n=62). Fib and hs-CRP were determined before and after treatment by day 3 and day 7 in all patients.Result: No significant difference of fib [(4.02±0.13) g/L vs (4.10±0.15) g/L] and hs-CRP [(18.7±5.5) mg/L vs (19.6±5.7) mg/L] was found between ticagrelo group and clopidogrel group on day 3 following treatment. After 7 days treatment, both the level of fib [( 3.06±0.16) g/L vs (3.52±0.19) g/L] and hs-CRP [(7.1±4.2) mg/L vs (9.58±4.60) mg/L] in ticagrelo group was significantly decreased compared with those in clopidogrel group.Conclusion:Compared with clopidogrel,ticagrelor has stronger thrombus inhibitory effects and anti-inflammatory effects in patients with NSTE-ACS.
- non-ST-elevation acute coronary syndromes /
- ticagrelo /
- clopidogrel /
- fibrinogen /
- high-sensitive Creactive protein

HTML全文

参考文献(9)

[1]	AMSTERDAM E A,WENGER N K,BRINDIS R G,et al.2014AHA/ACC guideline for the management of Patients with non-ST-elevation acute coronary syndromes:executive summary:a report of the american college of cardiology/american heart association task force on practice guidelines[J].J Am Coll Cardiol,2014,64:e139-e228.
[2]	MEIER P,LANSKY A J,BAUMBACH A.Almanac 2013:acute coronary syndromes[J].Turk Kardiyol Dern Ars,2013,41:755-764.
[3]	BARYSHEVA N A B,MERKULOVA I N M,SHABANOVA M S S,et al.Assessment of Coronary Plaques in Patients With Acute Coronary Syndrome Without Persistent ST-Segment Elevation[J].Kardiologiia,2015,55:5-11.
[4]	YANG Y,LEWIS J P,HULOT J S,et al.The pharmacogenetic control of antiplatelet response:candidate genes and CYP2C19[J].Expert Opin Drug Metab Toxicol,2015,11:1599-1617.
[5]	STORELLI F,DAALI Y,DESMEULES J,et al.Pharmacogenomics of Oral Antithrombotic Drugs[J].Curr Pharm Des,2016,22:1933-1949.
[6]	GURBEL P A,BLIDEN K P,BUTLER K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study[J].Circulation,2010,121:1188-1199.
[7]	THOMAS M R,OUTTERIDGE S N,AJJAN R A,at al.Platelet P2Y12Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model[J].Arterioscler Thromb Vasc Biol,2015,35:2562-2570.
[8]	TUNJUNGPUTRI RN,RIKSEN N,RONGEN G,et al.Differential effects of platelets and platelet inhibition by ticagrelor on TLR2-and TLR4-mediated inflammatory responses[J].Thromb Haemost,2015,113:1035-1045.
[9]	ZHOU B,PAN Y,YU Q,et al.Fibrinogen facilitates atherosclerotic formation in Sprague-Dawley rats:A rodent model of atherosclerosis[J].Exp Ther Med,2013,5:730-734.